search
Back to results

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

Primary Purpose

Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
thyroxine
Placebo
A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Sponsored by
Attikon Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus focused on measuring Diabetes mellitus, thyroxine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland.
  • Recreationally active
  • With stable body weight and diet during the last two months.

Exclusion Criteria:

  • Any systemic disease(besides glucose abnormalities)
  • Any medication therapy
  • Diabetic complications

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    thyroxine in eythyroid diabetics

    thyroxine in euthyroid healthy humans

    placebo in euthyroid diabetics

    Arm Description

    50 μg of thyroxine once daily, for 2 months.

    50 μg of thyroxine once daily, for 2 months.

    50 μg of placebo once daily, for 2 months.

    Outcomes

    Primary Outcome Measures

    area under the glucose uptake versus time curve-AUC
    Muscle glucose uptake following meal ingestion

    Secondary Outcome Measures

    Plasma glucose levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma insulin levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma triglyceride levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma total cholesterol levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma LDL-cholesterol levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma HDL-cholesterol levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma Apo-A levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma Apo-B levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma Lp(α) levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma NEFA levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma glycerol levels following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Muscle blood flow following meal ingestion
    area under the plasma concentration versus time curve-AUC
    Plasma thyroid hormones
    measure of plasma concentration
    glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG
    area under the curve of 6-NBDG uptake by monocytes under insulin stimulation
    % GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.
    Number of participants with adverse events

    Full Information

    First Posted
    July 26, 2015
    Last Updated
    July 27, 2015
    Sponsor
    Attikon Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02509858
    Brief Title
    The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.
    Official Title
    The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, at All Stages of Type 2 Diabetes Mellitus.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2009 (undefined)
    Primary Completion Date
    February 2014 (Actual)
    Study Completion Date
    July 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Attikon Hospital

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    We investigated the effect of the administration of small doses of thyroxine to healthy humans and patients with type 2 diabetes on postprandial forearm muscle glucose uptake, insulin sensitivity indices, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.
    Detailed Description
    The present open-labeled, randomized and placebo-controlled study was undertaken in euthyroid type 2 diabetic patients and healthy humans, to examine the effect of administration of small doses of thyroxine within the euthyroid range, on muscle glucose disposal, postprandial insulin sensitivity, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.This was investigated with the arteriovenous-difference technique after the consumption of a mixed meal and the in vitro study of a glucose analogue(6-NBDG) uptake by the peripheral monocytes. Subjects and Methods: Eleven euthyroid, treatment naive, type-2 diabetic patients with a micronodular texture of the thyroid gland and eleven healthy euthyroid subjects, were studied before and after administration of 50 μg of thyroxine once daily for 2 months. In parallel, a placebo group was also studied. Eleven euthyroid treatment-naïve subjects with type 2 diabetes and a micronodular texture of the thyroid gland, matched for age, sex, BMI, and basal thyroid function, were studied before and after administration of a placebo, once daily for 2 months. Experimental protocol: All subjects were admitted to the hospital at 0700 h after an overnight fast and had the radial artery (A) and a forearm deep vein (V) catheterized. A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein) was given at least 1 h after catheter insertion and was consumed within 20 min. Blood samples were drawn from both sites before the meal (at -30 and 0 min) and at 30- to 60-min intervals for 300 min thereafter for measurements of thyroid hormones,glucose, total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides, Apolipoprotein A1, Apolipoprotein BII and Lp(a).Forearm blood flow was measured with strain-gauge plethysmography. After the first meal tolerance test, treatment with 50μg of thyroxine or placebo, once daily, was initiated for a 2-month period. Then a second identical test was repeated. Special care was taken in order to avoid the induction of subclinical hyperthyroidism, that is suppression of TSH below 0.27 μU/ml, as it has recently been shown that the latter is also an insulin-resistant condition.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus
    Keywords
    Diabetes mellitus, thyroxine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    33 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    thyroxine in eythyroid diabetics
    Arm Type
    Active Comparator
    Arm Description
    50 μg of thyroxine once daily, for 2 months.
    Arm Title
    thyroxine in euthyroid healthy humans
    Arm Type
    Active Comparator
    Arm Description
    50 μg of thyroxine once daily, for 2 months.
    Arm Title
    placebo in euthyroid diabetics
    Arm Type
    Placebo Comparator
    Arm Description
    50 μg of placebo once daily, for 2 months.
    Intervention Type
    Drug
    Intervention Name(s)
    thyroxine
    Other Intervention Name(s)
    T4
    Intervention Description
    treatment with 50μg of thyroxine once daily for two months.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    treatment with 50μg of placebo, once daily, for two months.
    Intervention Type
    Other
    Intervention Name(s)
    A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
    Primary Outcome Measure Information:
    Title
    area under the glucose uptake versus time curve-AUC
    Description
    Muscle glucose uptake following meal ingestion
    Time Frame
    Time Frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Secondary Outcome Measure Information:
    Title
    Plasma glucose levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma insulin levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma triglyceride levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma total cholesterol levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma LDL-cholesterol levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma HDL-cholesterol levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma Apo-A levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma Apo-B levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma Lp(α) levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma NEFA levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma glycerol levels following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Muscle blood flow following meal ingestion
    Description
    area under the plasma concentration versus time curve-AUC
    Time Frame
    0, 30, 60, 90, 120, 180, 240, 300 min postmeal
    Title
    Plasma thyroid hormones
    Description
    measure of plasma concentration
    Time Frame
    baseline
    Title
    glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG
    Description
    area under the curve of 6-NBDG uptake by monocytes under insulin stimulation
    Time Frame
    baseline to 600 sec
    Title
    % GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.
    Time Frame
    baseline
    Title
    Number of participants with adverse events
    Time Frame
    300 min postmeal

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland. Recreationally active With stable body weight and diet during the last two months. Exclusion Criteria: Any systemic disease(besides glucose abnormalities) Any medication therapy Diabetic complications
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    GEORGE DIMITRIADIS, MD, Phd
    Organizational Affiliation
    2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, Attikon Hospital
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

    We'll reach out to this number within 24 hrs